Navigation Links
FDA Collaboration Seeks to Speed Development of Pneumococcal Vaccines for Children in Developing Countries
Date:2/1/2010

PATH supports FDA advancement of a key step in vaccine development

SILVER SPRING, Md., Feb. 1 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration (FDA) today announced a collaboration with PATH to advance development of a vaccine to protect children against diseases caused by Streptococcus pneumoniae (pneumococcus), especially pneumonia.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Worldwide, the bacterium also causes infections of the brain (meningitis), blood (sepsis), and middle ear (otitis media) and each year kills about 1 million children younger than 5 years of age. The collaboration aims to improve the techniques used to produce effective, safe, and affordable vaccines against pneumococcal disease for children in the developing world.

PATH is an international nonprofit organization based in Seattle that creates sustainable, culturally relevant, and affordable solutions to help communities worldwide to break cycles of poor health.

The collaborative project, expected to run for two years, is being conducted under the Cooperative Research and Development Agreement (CRADA) program. The program allows federal laboratories and businesses to form partnerships that help expedite research activities.

Under the agreement, PATH will help the FDA obtain materials needed for the agency to develop the conjugate vaccine technology. PATH also will provide approximately $480,000 to the FDA for the development of both the conjugation technology and tests to determine if the carrier proteins are properly linked to the polysaccharides.

The goal of the CRADA is to evaluate the application of Center for Biologics Evaluation and Research (CBER) conjugation technology to pneumococcal vaccines. If it holds promise for fulfilling the goal of providing safe, effective, and affordable pneumococcal vaccines, the CRADA permits transfer of the technology to the China National Biotec Group's Chengdu Institute of Biological Products, and eventually to groups in other developing countries as appropriate.

"CBER will use its scientific expertise to develop technology for a vaccine against pneumococcal disease that is safe and effective," said Karen Midthun, M.D., acting director of the FDA's CBER. "The collaboration with PATH is an example of how the FDA applies technologies it develops to public health issues in the United States and throughout the world under the agency's Critical Path Initiative."

The goal of the FDA's work is to improve the efficiency of a key technology in the development of pneumococcal conjugate vaccine candidates. The technology is used to link a piece of the bacterium's surface coating, a polysaccharide made up of long chains of sugars, to a special molecule called a carrier protein in a process called conjugation.

When carrier proteins are joined with the polysaccharides, they significantly increase the strength of the immune response. Without these proteins, the polysaccharides by themselves would not trigger an adequate immune response in young children.

CBER conjugation technology has already been used by the Meningitis Vaccine Project—a partnership between PATH and the World Health Organization—for the development of a conjugate vaccine to prevent meningococcal meningitis in Africa.

For more information:

Collaborative Opportunities –FDA Technology Transfer Program

http://www.fda.gov/ScienceResearch/CollaborativeOpportunities/default.htm

PATH Web site

http://www.path.org

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

RELATED LINKS
http://www.fda.gov/
http://www.path.org/

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
2. American Red Cross and FedEx Announce Collaboration to Help Small Businesses Get Prepared for Disaster
3. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
4. NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
5. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
6. London School of Hygiene to play key role in global collaboration on adverse drug reactions
7. Chemizon Announces Research Collaboration Expansion With Takeda
8. Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc.
9. American Diabetes Association Announces Three Year Collaboration With The Dignity Memorial(R) Network
10. Diet.com Enters Strategic Collaboration To Support Microsoft HealthVault
11. AMRI and Cystic Fibrosis Foundation Launch Major Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... ... Miami native and local periodontist Dr. John Paul Gallardo is celebrating ... 1991 that this journey would have taken me into so many learning experiences both ... has pioneered implant dentistry innovation, evolving into an internationally recognized leader in the industry. ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... today launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced ... farmers produce more and better food, with fewer resources. It highlights the business’ ...
(Date:4/26/2017)... Doylestown, Pa. (PRWEB) , ... ... ... Solutions division, which provides an agile ecosystem and domain expertise for sponsors ... end-to-end, configurable randomization and trial supply management (RTSM) software platform. Bioclinica ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, a ... first in a new class of photodynamic cosmetics (PDC). , Allumera® is the ... reduce outward signs of aging, and minimize the appearance of pores – all ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... agreement to be the preferred physical therapy provider for Derby City CrossFit, effective ... Derby City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
Breaking Medicine Technology: